

The Next Frontier of Blood Cancer Therapy

TRADITIONAL CAR-T (Current State)



Long
Manufacturing Wait
(2–5 Weeks)

Complex,
Patient-Specific

NEXT FRONTIER: OFF-THE-SHELF & BEYOND



ALLOGENEIC CAR-T
Ready When Needed
Uses healthy donor cells,
eliminates wait




**73%
RESPONSE**

with Lower Toxicity
(CAR-NK cells: No GVHD or CRS)

BISPECIFICS

CAR-T Without the Lab



T-CELL

CANCER

Simple molecules physically
link cells, no gene engineering

PHARMACY-LEVEL CONVENIENCE

FEATURE	 AUTOLOGOUS CAR-T	 BISPECIFIC ANTIBODIES
Availability	2–5 Week Wait (One-time infusion)	Immediate (Off-the-shelf), Weekly or Bi-weekly dosing
Treatment	Potentially Deeper/Durable	Remission: High response, continuous care



THE 5-YEAR HORIZON IN VIVO

Future tech: Deliver gene
engineering directly into
body via nanoparticles

↓
Bypassing the Lab

